Homepage > Company > Media > Pharma News > 2023 > Coherus Acquires Rights From Klinge Biopharma for Eylea Biosimilar Candidate

Coherus Acquires Rights From Klinge Biopharma for Eylea Biosimilar Candidate

Coherus BioSciences has inked a licensing deal with Klinge Biopharma for the exclusive U.S. commercial rights to FYB203, Klinge’s investigational biosimilar of Regeneron’s blockbuster drug Eylea (aflibercept).

FYB203 is currently in a phase 3 study to evaluate its safety and efficacy compared with Eylea in patients with wet age-related macular degeneration.

Under the deal, Klinge will receive an upfront payment of approximately $32.5 million. The transaction is expected to be completed in the first quarter of this year.

Coherus plans on filing a biologics license application to the FDA for the biosimilar candidate later this year and aims to launch the product in 2025.

January 19, 2023

https://www.fdanews.com/

Read also

Three scientists win Nobel Prize

Three scientists win Nobel Prize in chemistry for creating new molecular structure

Boehringer

Boehringer bags FDA okay for new pulmonary fibrosis drug

Editas Medicine reports 90% LDL-C reduction in preclinical studies

CAMBRIDGE, Mass. - Editas Medicine, Inc., whose stock has surged over 260% in the past six months according to InvestingPro data

China accounts for one-fifth of global drugs in development

China-based companies are responsible for 20% of drugs in development globally, reflecting the powerhouse role the country has embraced in the pharmaceutical industry.